GlassScriptPhysician profile
Emina Begovic
NPI 1881241610
$3,723.20
in general payments reported to CMS, 2019-2025
21 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $667 · 2023: $778 · 2024: $1,132 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,064.38 | 2021-2025 | |
| Blueprint Medicines Corporation | $496.54 | 2022-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $362.94 | 2022-2025 | Iclusig |
| Sobi, INC | $300.00 | 2024 | |
| Celgene Corporation | $257.73 | 2022-2025 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $213.91 | 2023-2025 | Ojjaara, Shingrix |
| Amgen INC. | $183.26 | 2021-2023 | Blincyto |
| Daiichi Sankyo INC. | $106.87 | 2023-2025 | Injectafer, Vanflyta |
| Genzyme Corporation | $101.58 | 2025 | |
| Stemline Therapeutics INC. | $88.81 | 2022-2025 | Elzonris |
| Abbvie INC. | $80.55 | 2024 | |
| Taiho Oncology, INC. | $79.28 | 2022-2023 | |
| Kite Pharma, INC. | $66.03 | 2024 | Yescarta |
| Rigel Pharmaceuticals, INC. | $63.04 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Napo Pharmaceuticals INC | $59.58 | 2025 | Gelclair Concentrated Oral Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $50.87 | 2023-2024 | |
| Cti Biopharma Corp. | $42.88 | 2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2023 | Reblozyl |
| Azurity Pharmaceuticals, INC. | $27.65 | 2025 | Danziten |
| Genmab U.S., INC. | $27.49 | 2023 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $19.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emina Begovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.